×

Biotech and Pharmaceuticals Medicine

  • The push back on Sovaldi

    Insurance companies are hurting from the high cost of hepatitis C drug Sovaldi. Arthur Caplan, NYU Langone Medical Center, and CNBC's Bertha Coombs, share their opinions.

  • CRE, one of the worst of the superbugs, is spreading in some hospitals, and there's worry that cases are under-reported.

  • A Liberian man is being tested for the deadly Ebola virus in Nigeria's commercial capital of Lagos, a megacity of 21 million people.

  • Gilead Sciences delivered quarterly earnings and revenue that topped analysts' expectations on Wednesday.

  • Biogen CEO: Want to stop inversions? Reform tax code

    CNBC's Meg Tirrell speaks to Dr. George Scangos, Biogen Idec CEO, about the company's Q2 earnings surge, drug pipeline, and America's tax code. Scangos says we need a corporate tax rate that is competitive with rest of the world and a territorial tax system.

  • Faber Report: Puma Biotech surges

    CNBC's David Faber reports Puma Biotechnology surges on positive results for a breast cancer drug.

  • Puma Biotechnology's experimental breast cancer drug met its main goal in a late-stage trial, but the options market is sensing something funky.

  • FedEx indicted for prescription roulette

    CNBC's Scott Cohn reports FedEx has been indicted on 15 criminal counts for helping Internet pharmacies deliver drugs to buyers in the U.S. without prescriptions.

  • Next global epidemic?

    CNBC's Meg Tirrell reports which biotech companies are working on what analysts say could be the next big biotech catalyst known as NASH, or nonalcoholic steatohepatitis.

  • Government health workers administer blood tests to check for the Ebola virus in Kenema, Sierra Leone, June 25, 2014.

    Hundreds have died in West Africa from the Ebola virus. With no known cure and a high mortality rate, alarm is real.

  • Most millennials use alternative medicine to maintain wellbeing rather than cure existing sicknesses. The Fiscal Times reports.

  • The fight against Alzheimer's

    CNBC's Meg Tirrell reports there are currently 67 medicines in development for Alzheimer's, with the biggest players in the space including Eli Lilly, Roche/Genentech and Biogen.

  • The doctor will see you now

    In a continuing effort to cut costs and make medical care more convenient, insurers and employers are starting to embrace telemedicine - seeing a doctor online. Bertha Coombs looks at how telemedicine works, and how widespread the practice could become.

  • Blazing the pot industry trail

    Former Governor Gary Johnson, (R-N.M.), discusses the medical marijuana movement, and his high hopes for expanding the pot industry. Johnson also explains the medical benefits of oil-based cannabis.

  • Washington weed on sale

    Bob Leeds, Sea of Green Farms, is a licensed marijuana grower in the state of Washington. Leeds discusses his upstart progression and says he has invested about $2 million in the process to date.

  • Legal pot in Washington

    Teresa Yuan, King TV, reports from one of the first legal marijuana shops in the state of Washington.

  • Protect yourself from fake medicine

    CNBC's Scott Cohn follows up on his investigation into the high cost of prescription drugs and reports how consumers can protect themselves from getting fake medicine.

  • White House reacts to SCOTUS contraception ruling

    Pro-life and pro-choice demonstrators eagerly awaited the U.S. Supreme Court decision on contraception on Monday. CNBC's Hampton Pearson reports on the ruling.

  • Vertex CEO on big cystic fibrosis breakthrough

    CNBC's Meg Tirrell speaks to Vertex Pharmaceuticals CEO Dr. Jeffrey Leiden, about its promising two-drug cystic fibrosis treatment, and what it means for sufferers of the disease. Leiden also explains what goes into the pricing of an "orphan drug."

  • Vertex soars on cystic fibrosis innovation

    CNBC's Meg Tirrell reports Vertex Pharmaceuticals' cystic fibrosis combination of Kalydeco and Lumacaftor has expanded their patient population.